Tencent-Backed J&T Global Express Swung to Profit in First Half
By Jiahui Huang
Tencent-backed J&T Global Express swung to profit in the first half of the year, supported by lower share-based payments and expenses as well as strong overseas sales.
The Chinese logistics company said Monday that its net profit for the first half of the year was $27.6 million, compared with a net loss of $641.0 million a year earlier.
Revenue rose 10% to $4.86 billion during the period, J&T Global said in an earnings report.
The Shanghai-based company said its selling, general and administrative expenses dropped sharply to $381.7 million from $1.77 billion a year earlier. That came after it significantly lowered share-based payments and expenses, it said.
The company's aggressive expansion abroad has yielded some positive results. Revenue in new markets including Saudi Arabia, the United Arab Emirates, Mexico, Brazil and Egypt more than doubled to $291.6 million in the first half of 2024, thanks to rapid growth in parcel volumes, the company said.
J&T Global said its deepening cooperation with both foreign and local e-commerce platforms has supported its sales.
The company's shares finished the day up more than 6% in Hong Kong trading, but are still down 54% so far this year.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
August 19, 2024 06:02 ET (10:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks